ESMO 2021 | mHSPC prognostic subgroups

Silke Gillessen, MD, PhD, University of Lugano, Lugano, Switzerland and the Oncology Institute of Southern Switzerland, Bellinzona, Switzerland, outlines novel factors used to divide patients with metastatic hormone-sensitive prostate cancer (mHSPC) into different prognostic subgroups. To begin with, it has been shown that patients with de novo metastatic disease and patients who have undergone radical prostatectomy or radiotherapy have different prognoses. In addition, patients with liver and bone metastases have worse prognoses in comparison to other patients. It is important to define prognostic subgroups to identify patients requiring more or less intensive treatment regimens. This interview took place at the European Society for Medical Oncology (ESMO) 2021 congress.